Target intelligence / Profile preview

Down-regulator of transcription 1 (DR1)

Target
DR1
Molecular classification
Transcription factor, Repressor protein, Histone modification (as part of the ATAC complex with histone acetyltransferase activity), TBP-associated phosphoprotein
01

Overview

Down-regulator of transcription 1 (DR1) is a TBP (TATA box-binding protein)-associated phosphoprotein that functions as a transcriptional repressor, affecting both basal and activated RNA polymerase II-dependent gene expression. DR1 contains a histone fold motif, TBP-binding domain, and a glutamine/alanine-rich region. It regulates transcription by binding TBP and forming a heterodimer with DRAP1, inhibiting assembly of the transcription preinitiation complex. Additionally, DR1 is a component of the ATAC complex, which has histone acetyltransferase activity. The protein influences chromatin organization and may open new directions for targeted drug discovery, though no established drugs directly interact with DR1 yet.

Other names
Down-regulator of transcription 1Protein Dr1DR1NC2-betaNegative cofactor 2-betaNegative cofactor 2NC2NC2BNCB2TATA-binding protein-associated phosphoproteinDR1LLOC100910207NC2-β1700121L09RikHGNC:3017UniProt Q01658Ensembl ENSG00000117505
02

Mechanism of action

Transcriptional repression via interaction with TATA-binding protein (TBP) and formation of repressor complexes (with DRAP1), which block assembly of preinitiation complexes and the association of other transcription factors (TFIIA/TFIIB) with TBP. Modulation of chromatin/histone acetylation status (via ATAC complex).

03

Biological functions

Transcription repression (affecting both basal and activated transcription)Regulation of RNA polymerase II transcriptionChromatin organizationComponent of the ATAC complex (involved in histone acetylation on H3 and H4)Protein-protein interaction (notably forms a heterodimer with DRAP1)DNA binding
04

Disease associations

Other (documented associations with rare conditions Trichostrongylosis, Oesophagostomiasis; therapeutic role under investigation but no major disease link established yet)
05

Safety considerations

Unclear; as a transcriptional repressor, broad modulation of DR1 may have unpredictable effects on gene expression, cellular phenotype, and cell viability
06

Interacting drugs

None clearly established or clinically validated to date; protein is under active investigation for potential modulation by small molecules
07

Biomarkers

None established for clinical patient selection or monitoring, as DR1 is primarily a mechanistic research target

Beyond the preview

Go deeper on Down-regulator of transcription 1 (DR1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Down-regulator of transcription 1 (DR1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call